These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36163324)

  • 1. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
    Tang S; Shen Y; Wei X; Shen Z; Lu W; Xu J
    Cell Death Dis; 2022 Sep; 13(9):826. PubMed ID: 36163324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
    Giansanti M; De Gabrieli A; Prete SP; Ottone T; Divona MD; Karimi T; Ciccarone F; Voso MT; Graziani G; Faraoni I
    J Pharmacol Exp Ther; 2021 Jun; 377(3):385-397. PubMed ID: 33820831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
    Han C; McNamara B; Bellone S; Harold J; Manara P; Hartwich TMP; Mutlu L; Yang-Hartwich Y; Zipponi M; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Mar; 170():172-178. PubMed ID: 36706643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    Shim JI; Ryu JY; Jeong SY; Cho YJ; Choi JJ; Hwang JR; Choi JY; Sa JK; Lee JW
    Gynecol Oncol; 2022 May; 165(2):270-280. PubMed ID: 35305818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
    Kristeleit RS; Moore KN
    Ann Oncol; 2022 Oct; 33(10):989-991. PubMed ID: 35964823
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
    Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy.
    Santiago-O'Farrill JM; Blessing Bollu A; Yang H; Orellana V; Pina M; Zhang X; Liu J; Bast RC; Lu Z
    Mol Cancer Res; 2024 Sep; 22(9):840-851. PubMed ID: 38780897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
    Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
    Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
    Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRABP2 reduces the sensitivity of Olaparib in ovarian cancer by downregulating Caspase-8 and decreasing the production of reactive oxygen species.
    Zeng S; Xu Z; Liu Y; Zhou S; Yan Y
    Chem Biol Interact; 2024 Apr; 393():110958. PubMed ID: 38493911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
    Fong PC; Yap TA; Boss DS; Carden CP; Mergui-Roelvink M; Gourley C; De Greve J; Lubinski J; Shanley S; Messiou C; A'Hern R; Tutt A; Ashworth A; Stone J; Carmichael J; Schellens JH; de Bono JS; Kaye SB
    J Clin Oncol; 2010 May; 28(15):2512-9. PubMed ID: 20406929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
    Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
    Kwon M; Jang H; Kim EH; Roh JL
    Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.